DTIL — Precision Biosciences Share News
0.000.00%
Last trade - 00:00- $183.27m
- $118.15m
- $34.26m
U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge
Precision BioSciences rises as FDA fast-tracks gene therapy for muscle‑wasting disease
U.S. STOCKS ON THE MOVE-Micron, McDonald's, Generac
U.S. STOCKS ON THE MOVE-Klaviyo, Frontier Group, Wabtec
U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy
Precision BioSciences jumps after FDA clears trial for muscle‑wasting disease therapy
Brief: Precision Biosciences Receives U.S. FDA Clearance Of Investigational New Drug Application For First-In-Class Pbgene-Dmd For Treatment Of Duchenne Muscular Dystrophy
Brief: Precision Biosciences Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing
Brief: Precision BioSciences Announces $75 Million Offering Of Common Stock, Pre-Funded Warrants And Warrants
Precision BioSciences Q3 revenue falls sharply
Brief: Precision Biosciences Announces Late-Breaking Oral Presentation For Pbgene-Hbv At Aasld The Liver Meeting® 2025
Brief: Precision BioSciences Presents Phase 1 PBGENE-HBV Trial Data At HBV Cure Symposium; Targets Chronic Hepatitis B
Brief: Precision Biosciences Announces U.S. Patent Covering PBGENE-HBV For Chronic Hepatitis B And Updates Program Status
Precision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Precision BioSciences Announces Phase 1 Safety And Efficacy For Cohort 1, Lowest Dose Level In Eliminate-B, A First-In-Human Trial Of Pbgene-Hbv For Chronic Hepatitis B
Precision BioSciences Inc expected to post a loss of $1.57 a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of $1.57 a share - Earnings Preview
Precision BioSciences rises after FDA's 'orphan drug' tag for muscle disorder therapy
Brief: Precision Biosciences Receives FDA Orphan Drug Designation For Pbgene-Dmd For The Treatment Of Duchenne Muscular Dystrophy